ST Humanwell (600079.SH) subsidiary obtains U.S. FDA approval number for Diltiazem Hydrochloride Tablets

Zhitong Finance APP News, ST Humanwell (600079.SH) announced that its controlling subsidiary Yichang Humanwell Pharmaceutical Co., Ltd. (referred to as "Yichang Humanwell") recently received approval from the U.S. Food and Drug Administration (FDA) for Diltiazem Hydrochloride Tablets. The drug is primarily indicated for the treatment of chronic stable angina and angina caused by coronary artery spasm. This approval marks that Yichang Humanwell has obtained the qualification to sell the product in the U.S. market, which will have a positive impact on the company's expansion into the U.S. generic drug market. Yichang Humanwell will subsequently actively advance preparations for launching the product in the U.S. market.